India Montelukast Intermediate Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria)- Forecast to 2035

India Montelukast Intermediate Market Overview

As per MRFR analysis, the India Montelukast Intermediate Market Size awas estimated at 0.52 (USD Million) in 2023. The India Montelukast Intermediate Market Industry is expected to grow from 0.54 (USD Million) in 2024 to 1.8 (USD Million) by 2035. The India Montelukast Intermediate Market CAGR (growth rate) is expected to be around 11.604% during the forecast period (2025 - 2035).

Key India Montelukast Intermediate Market Trends Highlighted

The India Montelukast Intermediate Market is experiencing a variety of substantial trends that are indicative of the changing healthcare landscape. The rising prevalence of respiratory diseases, particularly asthma and allergies, has stimulated demand for related medications, making it one of the primary market drivers. A consistent supply of effective therapeutic agents, such as Montelukast, is essential in light of the fact that respiratory maladies are a significant cause of morbidity in the nation, as indicated by data from the Ministry of Health and Family Welfare.

Furthermore, the market is being propelled by the increasing recognition of the significance of preventive healthcare among the Indian populace. The potential for establishing strategic partnerships with pharmaceutical companies and expanding production capacities to guarantee a consistent supply chain for Montelukast intermediates is an opportunity that should be investigated. Government initiatives, such as "Make in India," can be leveraged by local manufacturers to reduce their dependence on imports and promote domestic production.

Furthermore, the Indian market offers a significant opportunity for growth by capitalizing on technological advancements to enhance product quality and improve the efficiency of the manufacturing process. In recent years, there has been a significant transition toward online platforms for pharmaceutical purchases, which the pandemic and evolving consumer behavior have influenced. The acquisition of medications is becoming increasingly popular through e-commerce channels, which offer consumers convenient access to Montelukast and related products.

Furthermore, the biotechnology sector is expected to experience a surge in investment, which is expected to stimulate research and development, resulting in the development of improvements in asthma management and related therapies. In general, the India Montelukast Intermediate Market is well-positioned for future growth due to the convergence of increasing healthcare awareness, rising respiratory disorders, and technological advancements.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

India Montelukast Intermediate Market Drivers

Rising Incidence of Respiratory Disorders

The India Montelukast Intermediate Market Industry is witnessing significant growth due to the increasing prevalence of respiratory disorders such as asthma and allergic rhinitis. According to the National Center for Biotechnology Information, the estimated prevalence of asthma in India is about 15% in urban areas and 5% in rural areas. This translates to a staggering number of approximately 20 million individuals being affected by asthma alone.

As Montelukast has been widely recognized for its efficacy in managing these conditions, its demand in India is projected to rise accordingly. Additionally, the Indian government's initiatives, such as the National Health Mission, aim to address healthcare issues related to respiratory diseases, further bolstering the market's growth potential. Institutions like the All India Institute of Medical Sciences are investing in Research and Development (R&D) pertaining to asthma treatments, thereby enhancing the market landscape for Montelukast intermediates.

Growing Awareness About Preventive Healthcare

In India, there is a growing trend towards preventive healthcare, which is driving the demand for effective medications like Montelukast. Health campaigns initiated by the Ministry of Health and Family Welfare have raised awareness regarding chronic diseases and the importance of medication adherence. Reports indicate that the Indian pharmaceutical market is projected to grow at a compound annual growth rate of 11 to 12% over the next decade.

This trend highlights the potential for increased consumption of asthma medications, with Montelukast being a pivotal player in this arena. Organizations such as the Indian Pharmaceutical Association are supporting educational efforts that emphasize preventive healthcare, ultimately facilitating market improvements in the India Montelukast Intermediate Market.

Regulatory Support and Approval

The regulatory framework in India plays a crucial role in the growth of the India Montelukast Intermediate Market Industry. The Drug Controller General of India has streamlined its processes for approving new generic drugs, fostering a conducive environment for manufacturers to produce Montelukast. Recent amendments in drug regulations have expedited the approval timeline for medications, increasing the accessibility of Montelukast to consumers.

Additionally, pharmaceutical companies such as Sun Pharmaceutical Industries Ltd and Dr Reddy's Laboratories have filed multiple patents related to Montelukast intermediates, demonstrating their commitment to enhancing the production landscape in India. This regulatory support aids in making Montelukast more available at competitive prices, thus driving sales.

India Montelukast Intermediate Market Segment Insights

Montelukast Intermediate Market Application Insights

The Application segment of the India Montelukast Intermediate Market reflects a significant component of the overall industry, primarily focusing on therapeutic uses related to respiratory and allergic conditions. With the increasing prevalence of asthma in India, primarily among children and young adults, the demand for therapies that address this condition continues to rise. Growing awareness about asthma management, coupled with the rise in air pollution, has led to a greater emphasis on effective treatment options, bolstering growth in this area.

Allergic Rhinitis equally represents a vital application, given the high incidence of allergies triggered by environmental factors such as pollen, dust, and pollution. The ability of Montelukast to alleviate symptoms such as sneezing and nasal congestion contributes to its significant utilization in treating this condition. Furthermore, Bronchospasm, characterized by sudden constriction of the muscles in the walls of the bronchioles, is another critical aspect of the Montelukast Application segment.

Patients with chronic obstructive pulmonary disease (COPD) or asthma often experience bronchospasms, creating an ongoing demand for medications that provide rapid relief. The diverse potential of Montelukast in managing such conditions places it at the forefront of therapeutic strategies in the Indian market. Urticaria, which includes hives and skin reactions triggered by allergens or stress, adds another important dimension to the applications of Montelukast.

The rising awareness among individuals regarding allergic skin conditions and their management supports its relevance in the market. Overall, the Montelukast Application segment is characterized by a variety of health conditions, each driving demand for effective management solutions, supported by a backdrop of rising awareness and growing healthcare access in India. As such, the therapeutic significance of Montelukast for these conditions underlines its importance in improving patient quality of life and reflects broader trends in healthcare focusing on effective management of chronic conditions.

This multifaceted approach to healthcare is essential for addressing the diverse epidemiological landscape of India, wherein a significant portion of the population shares susceptibility to these ailments, fostering continuous growth in the Montelukast Intermediate Market. As a result, the application-focused strategies within the India Montelukast Intermediate Market signify not only the industry's potential for expansion but also highlight the crucial interplay between healthcare initiatives and patient need across varied treatment areas.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

India Montelukast Intermediate Market Key Players and Competitive Insights

The India Montelukast Intermediate Market is characterized by a diverse landscape influenced by various players engaged in the production and distribution of Montelukast intermediates, which are essential for the synthesis of Montelukast itself, a widely prescribed medication for asthma and allergies. The competitive dynamics of this market are shaped by the growing demand for allergy management and asthma treatment, coupled with the increasing number of pharmaceutical companies investing in research and development to innovate and enhance the manufacturing processes.

As a result, companies are striving to establish strong positions through strategic partnerships, supply chain optimizations, and by leveraging advancements in technology to secure their competitiveness in the marketplace. Intas Pharmaceuticals has carved a significant niche within the India Montelukast Intermediate Market by focusing on high-quality standards and efficient production practices. The company's strength lies in its robust research and development capabilities, which have enabled it to enhance its product offerings continuously.

Intas has established a wide distribution network across India, ensuring that its products are accessible to a broad base of consumers and healthcare providers. Furthermore, the company has invested in expanding its manufacturing facilities, catering specifically to the growing demands in the Montelukast segment, which showcases its commitment to maintaining a leading position in the market. This focus has contributed to Intas's ability to offer competitive pricing without compromising on quality, thereby solidifying its presence in the intermediate market.

Torrent Pharmaceuticals also plays a pivotal role in the India Montelukast Intermediate Market, recognized for its point of differentiation through consistent product innovation and a strong focus on quality. The company has developed a robust portfolio of key products associated with Montelukast intermediates, aimed at supporting the pharmaceutical industry's requirements for sustained supply. Torrent's strategic presence throughout various regions in India enhances its ability to serve diverse consumer needs effectively.

The company's strengths include agile manufacturing capabilities and a commitment to research that aligns with regulatory standards, providing it a competitive edge. Furthermore, Torrent Pharmaceuticals has engaged in various mergers and acquisitions in the past, which have helped expand its product line and bolster its market presence, facilitating a sustained focus on quality and timely delivery of its products within the Montelukast segment.

Key Companies in the India Montelukast Intermediate Market Include

• Intas Pharmaceuticals


• Torrent Pharmaceuticals


• Dr Reddy's Laboratories


• Siegfried AG


• Alkem Laboratories


• Sun Pharmaceutical Industries


• Zydus Cadila


• Lupin


• M S S Pharmaceuticals


• RPG Life Sciences


• Biocon


• Aurobindo Pharma


• Cipla


• Hetero Labs


• Wockhardt

India Montelukast Intermediate Market Industry Developments

The India Montelukast Intermediate Market has witnessed significant developments in recent months, with key players like Intas Pharmaceuticals, Torrent Pharmaceuticals, and Dr Reddy's Laboratories expanding their production capacities due to rising demand. In October 2023, Intas announced its plans to enhance its manufacturing facilities in Gujarat, aiming to increase output for key intermediates, including Montelukast, to further strengthen its position in the market.

Additionally, Torrent Pharmaceuticals has successfully received regulatory approvals for new Montelukast formulations, which are expected to boost its market share. In terms of mergers and acquisitions, Alkem Laboratories completed an acquisition of a local biotechnology firm in September 2023 to bolster its R&D capabilities in respiratory medications, drawing focus toward Montelukast derivatives.

Moreover, the overall market valuation for Montelukast in India has seen a steady growth of approximately 12% year-on-year, attributed to a rise in asthma and allergy cases. The competitive landscape remains active with companies like Aurobindo Pharma and Cipla also looking to innovate in the respiratory therapeutics segment. Major advancements in manufacturing technologies are enhancing the efficiency and cost-effectiveness of Montelukast production across the sector.

India Montelukast Intermediate Market Segmentation Insights

Montelukast Intermediate Market Application Outlook

• Asthma


• Allergic Rhinitis


• Bronchospasm


• Urticaria

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	0.52(USD Million)
MARKET SIZE 2024	0.54(USD Million)
MARKET SIZE 2035	1.8(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	11.604% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Intas Pharmaceuticals, Torrent Pharmaceuticals, Dr. Reddy's Laboratories, Siegfried AG, Alkem Laboratories, Sun Pharmaceutical Industries, Zydus Cadila, Lupin, M S S Pharmaceuticals, RPG Life Sciences, Biocon, Aurobindo Pharma, Cipla, Hetero Labs, Wockhardt
SEGMENTS COVERED	Application
KEY MARKET OPPORTUNITIES	Expanding asthma prevalence, Rising hybrid formulations, Increased generic competition, Growing export demand, Technological advancements in production
KEY MARKET DYNAMICS	growing asthma prevalence, increasing pharmaceutical demand, regulatory compliance challenges, competitive pricing pressures, supply chain disruptions
COUNTRIES COVERED	India